

The HA Drug Advisory Committee (DAC), comprising doctors, clinical pharmacologists and pharmacists, systematically appraises new drugs every three months. DAC is supported by expert panels which provide specialist views on the selection of drugs for individual specialties.

Drug Advisory Committee Apr 2018 Meeting Outcome

	Generic name	Brand name	Therapeutic Class	Meeting outcome	Primary reason for rejection ¹
1	Alectinib	Alecensa	Malignant disease and immunosuppression	Approved	N/A
2	Bedaquiline	Sirturo	Infections	Approved	N/A
3	Carfilzomib	Kyprolis	Malignant disease and immunosuppression	pending	Pending further information
4	Ceftolozane/tazobactam	Zerbaxa	Infections	Rejected	Alternative(s) available in HADF with comparable benefits
5	Eribulin	Halaven	Malignant disease and immunosuppression	pending	Pending further information
6	Everolimus	Afinitor	Malignant disease and immunosuppression	Approved	N/A
7	Infliximab	Remsima	Musculoskeletal and joint disease	Approved	N/A
8	Insulin glargine	Toujeo	Endocrine system	Rejected	Alternative(s) available in HADF with comparable benefits
9	Lenalidomide	Revlimid	Malignant disease and immunosuppression	pending	Pending further information
10	Lenvatinib	Lenvima	Malignant disease and immunosuppression	Approved	N/A
11	Nivolumab	Opdivo	Malignant disease and immunosuppression	pending	Pending further information
12	Palbociclib	Ibrance	Malignant disease and immunosuppression	Approved	N/A
13	Pertuzumab	Perjeta	Malignant disease and immunosuppression	Rejected	Insufficient evidence to demonstrate significant clinical outcome benefits
14	Secukinumab	Cosentyx	Skin	Approved	N/A
15	Tenofovir alafenamide	Vemlidy	Infections	pending	Pending further information
16	Ticagrelor	Brilinta	Cardiovascular system	Rejected	Insufficient evidence to demonstrate significant clinical outcome benefits
17	Timolol eye drops preservative free	Timo-COMOD	Eye	Approved	N/A
18	Vedolizumab	Entyvio	Gastro-intestinal system	Approved	N/A

¹ The evaluation embraces the principles of safety, efficacy and cost-effectiveness and takes into account other relevant factors, including international recommendations and practices, advance in technology, disease state, patient compliance, quality of life, actual experience in the use of drugs as well as views of professionals and patients groups.